Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 45 IN PLASTIC CONTAINER.
Head-to-head clinical analysis: MAGNESIUM SULFATE IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5 AND SODIUM CHLORIDE 0 45 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
Potassium chloride replaces potassium ions lost from the body; dextrose provides caloric energy; sodium chloride provides sodium and chloride ions to maintain electrolyte balance. Potassium is the major intracellular cation, essential for nerve conduction, muscle contraction, and acid-base balance.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
Intravenous infusion: 30 mEq potassium chloride in 1000 mL of D5 1/2NS, administered at a rate not exceeding 10 mEq/hour. Typical adult dose: 30-40 mEq/day, adjusted based on serum potassium.
None Documented
None Documented
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Terminal half-life not applicable for potassium; administered as a continuous infusion for correction of hypokalemia. In healthy individuals, serum potassium half-life is approximately 8-12 hours for distribution equilibration.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Primarily renal (>90% as potassium); minimal fecal or biliary elimination.
Category C
Category A/B
Electrolyte
Electrolyte